Результаты поиска

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials.

BackgroundAscorbate (vitamin C) has been evaluated as a potential treatment for cancer as an independent agent and in combination with standard chemotherapies. This review assesses the evidence for safety and clinical effectiveness of intravenous (IV) ascorbate in treating various types of cancer.MethodsSingle arm and randomized Phase I/II trials were included in this review. The PubMed, MEDLINE, and Cochrane databases were searched. Results were screened by three of the authors (GN, RP, and CJP) to determine if they met inclusion criteria, and then summarized using a narrative approach.Result

Совпадение в полном тексте источника
… The randomized Phase II trials, such as Docetaxel with or without Ascorbic Acid in Treating Patients with Metastatic Prostate Cancer ( NCT02516670 ) , provide a vehicle for assessing the clinical effectiveness of ascorbate in a high-quality, placebo-controlled setting. …

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.

The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1), a non-receptor protein tyrosine phosphatase, has been reported as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (STAT3) and linked to tumor development. In this present review, we will discuss the importance and function of SHP-1/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP

Совпадение в полном тексте источника
… Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Mol. Oncol. 2017;11:266–279. doi: 10.1002/1878-0261.12033. 70. …

Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.

BackgroundFollow-up care in breast cancer is still an issue of debate. Diagnostic methods are more sensitive, and more effective therapeutic options are now available. The risk of recurrence is not only influenced by tumour stage but also by the different molecular subtypes. This study was performed to evaluate the use of whole-body imaging combined with tumour marker monitoring for the early detection of asymptomatic metastatic breast cancer (MBC).MethodsThis analysis was performed as part of a follow-up study evaluating 813 patients with a median follow-up of 63 months. After primary therapy

Совпадение в полном тексте источника
… Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366 (2:109–119. doi: 10.1056/NEJMoa1113216. Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R. …

New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response.

In the genomics era, our main goal should be to identify large and meaningful differences in small, molecularly selected groups of patients. Classical phase I, II and III models for drug development require large resources, limiting the number of experimental agents that can be tested and making the evaluation of targeted agents inefficient. There is an urgent need to streamline the development of new compounds, with the aim of identifying "trials designed to learn", which could lead to subsequent "trials designed to conclude". Basket trials are often viewed as parallel phase II trials within

Совпадение в полном тексте источника
… Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial . …

Прогресс в развитии лекарственных средств на основе пептида: платформы для доставки, терапевтические средства и вакцины.

Успешное утверждение лекарств на основе пептида можно отнести на счет совместных усилий по целому ряду дисциплин. Интеграция новых методов разработки и синтеза лекарственных средств, отображение библиотечных технологий, систем доставки, достижений в области биоинженерии и искусственного интеллекта в значительной степени ускорила разработку новейших лекарств на основе пептида, эффективно устраняя препятствия, связанные с их характером, такие, как быстрое обезвреживание и деградация, необходимость субколичественной инъекции, ведущей к усилению дискомфорта пациентов, и в конечном итоге продвигая

Совпадение в полном тексте источника
… cancer;non-small cell lung sarcoma | NCT03486730 Phase I/II 4 | BT5528 792 | EphA2 binder | MMAE | Amide | Solid tumors EphA2-positive NSCLC | NCT04180371 Phase I 5 | BT8009 118 (Bicycle Therapeutics) | Nectin-4- binder | MMAE | Amide | Solid tumors | NCT04180371 Phase I/II 6 | TH1902 793 | TH19P01 | Docetaxel … In vitro, although the TH19P01 peptide itself exerted no antiproliferative or apoptotic effects when tested on TNBC-derived MDA-MB-231 cells, the docetaxel-TH19P01 conjugate (TH1902) demonstrated potent antiproliferative and antimigratory activities. 115 VEGFR-Targeting PDCs VEGFR-targeting PDCs, adopting …

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol.

Celastrol (CEL) is a natural pentacyclic triterpenoid demonstrating significant therapeutic properties against various diseases. However, the ambiguity of target information poses a significant challenge in transitioning CEL from a traditional remedy to a modern pharmaceutical agent. Recently, the emerging target discovery approaches of natural products have broadened extensive avenues for uncovering comprehensive target information of CEL and promoting its drug development. Herein, diverse target discovery strategies are overviewed for the pharmacological and toxicological studies of CEL, inc

Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.

The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody-drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term cancer survivors, an increasing incidence of previously unrecognized treatment-related toxicities has emerged. Among these, cardiovascular adverse events represent some of the most prevalent and clinically significant complications observed in both conventional chemother

Совпадение в полном тексте источника
… Taxanes Taxanes, including docetaxel, paclitaxel, and albumin-bound paclitaxel (nab-paclitaxel), are a class of antimitotic agents widely utilized in oncology. … In contrast, other taxanes, such as docetaxel, do not appear to potentiate doxorubicin-induced cardiotoxicity to the same extent [ 52 ]. 2.1.4. …

The role of interleukin-17 in inflammation-related cancers.

Emerging evidence indicates a correlation between inflammation and the development and progression of cancer. Among the various inflammatory signals, interleukin-17 (IL-17) family cytokines serve as a critical link between inflammation and cancer. IL-17 is a highly versatile pro-inflammatory cytokine that plays a pivotal role in host defense, tissue repair, the pathogenesis of inflammatory diseases, and cancer progression. During the early stages of tumorigenesis, IL-17 signaling directly promotes the proliferation of tumor cells. Conversely, IL-17 has been shown to exhibit antitumor immunity

Совпадение в полном тексте источника
… Some studies have found that IL-17E can induce c-RAF phosphorylation, ERK1/2 and p70 S6 kinase are involved in the proliferation and survival of tumor cells, aggravation of docetaxel resistance of breast cells, and induction of cyclin E (LMW-E) production, whose high level is closely related to the poor … In breast cancer, IL-17-mediated ERK activation and HER1 phosphorylation promote resistance to docetaxel-based chemotherapy and tyrosine kinase inhibition in breast cancer cells ( 201 , 202 ). …

mRNA vaccine development and applications: A special focus on tumors (Review).

Cancer is characterized by unlimited proliferation and metastasis, and traditional therapeutic strategies usually result in the acquisition of drug resistance, thus highlighting the need for more personalized treatment. mRNA vaccines transfer the gene sequences of exogenous target antigens into human cells through transcription and translation to stimulate the body to produce specific immune responses against the encoded proteins, so as to enable the body to obtain immune protection against said antigens; this approach may be adopted for personalized cancer therapy. Since the recent coronaviru

Совпадение в полном тексте источника
… Patients receiving docetaxel for metastatic castration-resistant prostate cancer showed no adverse effects when Kongsted et al ( 165 ) transfected DCs expressing numerous TAAs; ~50% of the research participants exhibited an immune response. …

Withania somnifera: Progress towards a Pharmaceutical Agent for Immunomodulation and Cancer Therapeutics.

Chemotherapy is one of the prime treatment options for cancer. However, the key issues with traditional chemotherapy are recurrence of cancer, development of resistance to chemotherapeutic agents, affordability, late-stage detection, serious health consequences, and inaccessibility. Hence, there is an urgent need to find innovative and cost-effective therapies that can target multiple gene products with minimal adverse reactions. Natural phytochemicals originating from plants constitute a significant proportion of the possible therapeutic agents. In this article, we reviewed the advances and t

Совпадение в полном тексте источника
… Liposomal drug delivery systems are being assessed in clinical trials, including the liposomal nano formulations of docetaxel, paclitaxel, irinotecan, and cisplatin [ 257 , 258 , 259 , 260 ]. …

An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.

Marine secondary metabolites are a promising source of unexploited drugs that have a wide structural diversity and have shown a variety of biological activities. These compounds are produced in response to the harsh and competitive conditions that occur in the marine environment. Invertebrates are considered to be among the groups with the richest biodiversity. To date, a significant number of marine natural products (MNPs) have been established as antineoplastic drugs. This review gives an overview of MNPs, both in research or clinical stages, from diverse organisms that were reported as bein

Совпадение в полном тексте источника
… The microtubule-stabilizing agents stimulate microtubule polymerization and include paclitaxel, docetaxel, the epothilones and discodermolide [ 125 , 126 ]. Microtubule-targeting agents are important anticancer drugs used in the treatment of breast, ovarian, and lung cancer [ 127 ]. …

Review: Oncolytic virotherapy, updates and future directions.

Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare their normal counterparts. OVs can access cells through binding to receptors on their surface or through fusion with the plasma membrane and establish a lytic cycle in tumors, while leaving normal tissue essentially unharmed. Multiple viruses have been investigated in humans for the past century. IMLYGIC™ (T-VEC/Talimogene Laherparepvec), a genetically engineered Herpes Simplex Virus, is the first OV approved for use in the United States and the European Union for patients with locally advanced or no

Совпадение в полном тексте источника
… . · Combinations with docetaxel [ 225 ], paclitaxel/ carboplatin [ 226 ] and gemcitabine [ 171 ] are well tolerated. · Clinical data for NSCLC, CRC, breast and pancreas cancers [ 120 – 122 , 124 , 227 ]. …

Oncogenic influences of neurotrophin receptors: Shedding light on Trk biology.

During critical stages of neurodevelopment, tropomyosin receptor kinase receptors, encoded by NTRK genes, exhibit temporally driven differential peaks of expression to properly guide the establishment of the peripheral and central nervous systems. In addition, these neuronal systems exhibit non-canonical regulation of surrounding tissues, impacting organogenesis, homeostasis, plasticity, and regeneration. The same processes that guide neurodevelopment, such as differentiation, plasticity, and neuronal survival, are also hijacked in cancer, making the NTRK family an ideal candidate to study. Th

Совпадение в полном тексте источника
… In the context of prostate cancer, inducing docetaxel resistance in prostate cancer cells leads to an overexpression of LINC01963. …

The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy.

Antibody-Drug Conjugates (ADCs) have achieved significant success in cancer therapy by combining the targeting specificity of monoclonal antibodies with cytotoxic payloads. However, the concomitant issue of drug resistance has become increasingly prominent, with primary mechanisms including alterations in target antigen expression, impaired drug transport, and inhibition of cell death pathways. ADCs have also shown emerging therapeutic potential in the treatment of autoimmune diseases; for instance, ABBV-3373 has achieved initial success in this area, yet it also faces unique challenges such a

Совпадение в полном тексте источника
… For instance, early studies (BP22572/ NCT00934856 ) found that combining T-DM1 with the classic taxane drug docetaxel could also enhance efficacy, but with more severe adverse reactions. …

Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.

The first part of this review highlighted the evolving landscape of atherosclerosis, noting emerging cardiometabolic risk factors, the growing impact of exposomes, and social determinants of health. The prominent role of atherosclerosis in the bidirectional relationship between cardiovascular disease and cancer was also discussed. In this second part, we examine the complex interplay between multimorbid cardio-oncologic patients, cardiometabolic risk factors, and the harmful environments that lend a "syndemic" nature to these chronic diseases. We summarize management strategies targeting disor

Adipocyte-Tumor Interactions in the Bone Marrow Niche: Implications for Metastasis and Therapy.

Bone metastases continue to be a major cause of morbidity and mortality in patients with advanced cancers, driven by the dynamic remodeling of the bone marrow niche. Traditionally viewed as passive space-fillers, bone marrow adipocytes (BMAs) are now recognized as active regulators of tumor growth, therapeutic resistance, and skeletal pathology. BMAs comprise a significant portion of the adult marrow space, particularly in aging and obesity, and facilitate metastatic colonization through various mechanisms. These include metabolic coupling, where adipocyte-derived fatty acids fuel tumor oxidat

Совпадение в полном тексте источника
… Atglistatin reverses the tumor-induced inflammatory/lipolytic program in bone-marrow adipocytes and restores docetaxel (chemotherapy medication) sensitivity in prostate cancer models of the bone niche [ 134 ]. …

Theranostics - a sure cure for cancer after 100 years?

Cancer has remained a formidable challenge in medicine and has claimed an enormous number of lives worldwide. Theranostics, combining diagnostic methods with personalized therapeutic approaches, shows huge potential to advance the battle against cancer. This review aims to provide an overview of theranostics in oncology: exploring its history, current advances, challenges, and prospects. We present the fundamental evolution of theranostics from radiotherapeutics, cellular therapeutics, and nanotherapeutics, showcasing critical milestones in the last decade. From the early concept of targeted d

Совпадение в полном тексте источника
… The TheraP study ( NCT03392428 ) was the first clinical trial to compare [¹⁷⁷Lu]Lu-PSMA-617 and cabazitaxel treatments in mCRPC patients who had progressed after docetaxel, showing that treatment with [¹⁷⁷Lu]Lu-PSMA-617 significantly increased the PSA 50 response rate (66% vs. 37%) and had a lower incidence … Fluorescence imaging revealed that docetaxel-nanoparticles colocalized with pulmonary metastatic foci, prolonged the retention of chemodrug at the diseased site, suppressed lesion growth, and boosted survival beyond 20 weeks post nodule engraftment. …

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.

Chemotherapy is an effortless and frequently used approach in cancer therapy. However, in most cases, it can only prolong life expectancy and does not guarantee a complete cure. Furthermore, chemotherapy is associated with severe adverse effects, one of the major complications of effective cancer therapy. In addition, newly published research outputs show that cancer stem cells are involved in cancer disease progression, drug resistance, metastasis, and recurrence and that they are functional in the trans-differentiation capacity of cancer stem cells to cancer cells in response to treatments.

Совпадение в полном тексте источника
… Well-designed clinical research studies that test the combination of a repurposed therapeutic agent and another cytotoxic agent can reduce the financial burden associated with novel drug discovery as drug repositioning passes toxicity and safety profiles. 157 The combination of docetaxel and sulforaphane …

Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.

Immunotherapy and targeted therapy have emerged as promising therapeutic options for cancer patients. Immunotherapies induce a host immune response that mediates long-lived tumor destruction, while targeted therapies suppress molecular mechanisms that are important for tumor maintenance and growth. In addition, cytotoxic agents and targeted therapies regulate immune responses, which increases the chances that these therapeutic approaches may be efficiently combined with immunotherapy to ameliorate clinical outcomes. Various studies have suggested that combinations of therapies that target diff

Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.

Natural killer (NK) cells are cellular components of the innate immune system that can recognize and suppress the proliferation of cancer cells. NK cells can eliminate cancer cells through direct lysis, by secreting perforin and granzymes, or through antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC involves the binding of the Fc gamma receptor IIIa (CD16), present on NK cells, to the constant region of an antibody already bound to cancer cells. Cancer cells use several mechanisms to evade antitumor activity of NK cells, including the accumulation of inhibitory cytokines, recruitment

Совпадение в полном тексте источника
… Health-related quality of life in KEYNOTE-010: a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. J Thorac Oncol (2019) 14:793–801. doi: 10.1016/j.jtho.2019.01.016 121. …